Journal of Gastric Cancer

The Korean Gastric Cancer Association (대한위암학회)
권호 표지
DOI QR코드

DOI QR Code

Multiregion Comprehensive Genomic Profiling of a Gastric Mixed Neuroendocrine-Nonneuroendocrine Neoplasm with Trilineage Differentiation

  • Farooq, Faheem (Department of Medicine, Stony Brook University Hospital) ;
  • Zarrabi, Kevin (Department of Medicine, Stony Brook University Hospital) ;
  • Sweeney, Keith (Department of Pathology, Stony Brook University Hospital) ;
  • Kim, Joseph (Department of Surgery, Stony Brook University Hospital) ;
  • Bandovic, Jela (Department of Pathology, Stony Brook University Hospital) ;
  • Patel, Chiraag (Department of Pathology, Stony Brook University Hospital) ;
  • Choi, Minsig (Department of Medicine, Stony Brook University Hospital)
  • Received : 2017.09.28
  • Accepted : 2018.06.04
  • Published : 2018.06.30
Download PDF
⟨ Previous Next ⟩

Abstract

Mixed neuroendocrine-nonneuroendocrine neoplasms (MiNENs) are a group of rare tumors previously known as mixed adenoneuroendocrine carcinomas (MANECs). The neuroendocrine component is high-grade and may consist of small-cell carcinoma or large-cell neuroendocrine carcinoma. The nonneuroendocrine component may consist of adenocarcinoma or squamous cell carcinoma. We report a unique case of a MiNEN with trilineage differentiation: large-cell neuroendocrine carcinoma, squamous cell carcinoma, and adenocarcinoma. The reported patient presented with symptoms of an upper gastrointestinal bleed and was ultimately diagnosed with a MiNEN with trilineage differentiation. This is the first report of this exceedingly rare tumor type to include next-generation sequencing of the 3 separate tumor entities. In addition, we review the current literature and discuss the role of next-generation sequencing in classifying and treating MiNEN tumors.

Keywords

References

  1. Lloyd RV, Osamura RY, Kloppel G, Rosai J. WHO Classification of Tumours of Endocrine Organs. 4th ed. Lyon: International Agency for Research on Cancer (IARC), 2017.
  2. Brathwaite S, Yearsley MM, Bekaii-Saab T, Wei L, Schmidt CR, Dillhoff ME, et al. Appendiceal mixed adeno-neuroendocrine carcinoma: a population-based study of the Surveillance, Epidemiology, and End Results registry. Front Oncol 2016;6:148.
  3. Sefr R, Nemec L, Fabian P, Fiala L. Mixed adenoneuroendocrine carcinoma (MANEC) of the gastrointestinal tract. Rozhl Chir 2017;96:41-44.
  4. La Rosa S, Marando A, Furlan D, Sahnane N, Capella C. Colorectal poorly differentiated neuroendocrine carcinomas and mixed adenoneuroendocrine carcinomas: insights into the diagnostic immunophenotype, assessment of methylation profile, and search for prognostic markers. Am J Surg Pathol 2012;36:601-611. https://doi.org/10.1097/PAS.0b013e318242e21c
  5. Bang YJ, Kim YW, Yang HK, Chung HC, Park YK, Lee KH, et al. Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial. Lancet 2012;379:315-321. https://doi.org/10.1016/S0140-6736(11)61873-4
  6. Frampton GM, Fichtenholtz A, Otto GA, Wang K, Downing SR, He J, et al. Development and validation of a clinical cancer genomic profiling test based on massively parallel DNA sequencing. Nat Biotechnol 2013;31:1023-1031. https://doi.org/10.1038/nbt.2696
  7. Levi Sandri GB, Carboni F, Valle M, Visca P, Garofalo A. Mixed adenoneuroendocrine gastric carcinoma: a case report and review of the literature. J Gastric Cancer 2014;14:63-66. https://doi.org/10.5230/jgc.2014.14.1.63
  8. Shen C, Chen H, Chen H, Yin Y, Han L, Chen J, et al. Surgical treatment and prognosis of gastric neuroendocrine neoplasms: a single-center experience. BMC Gastroenterol 2016;16:111. https://doi.org/10.1186/s12876-016-0505-5
  9. Shibuya H, Azumi N, Abe F. Gastric small-cell undifferentiated carcinoma with adeno and squamous cell carcinoma components. Acta Pathol Jpn 1985;35:473-480.
  10. Haratake J, Horie A, Inoshita S. Gastric small cell carcinoma with squamous and neuroendocrine differentiation. Pathology 1992;24:116-120. https://doi.org/10.3109/00313029209063636
  11. Pericleous M, Toumpanakis C, Lumgair H, Caplin ME, Morgan-Rowe L, Clark I, et al. Gastric mixed adenoneuroendocrine carcinoma with a trilineage cell differentiation: case report and review of the literature. Case Rep Oncol 2012;5:313-319. https://doi.org/10.1159/000339611
  12. Zhang W, Xiao W, Ma H, Sun M, Chen H, Zheng S. Neuroendocrine liver metastasis in gastric mixed adenoneuroendocrine carcinoma with trilineage cell differentiation: a case report. Int J Clin Exp Pathol 2014;7:6333-6338.
  13. Bae HI, Lee C, Jo YM, Kwon O, Yu W, Kim MS, et al. Gastric mixed adenoneuroendocrine carcinoma with squamous differentiation: a case report. J Pathol Transl Med 2016;50:318-321. https://doi.org/10.4132/jptm.2015.10.17
  14. Macdonald JS, Smalley SR, Benedetti J, Hundahl SA, Estes NC, Stemmermann GN, et al. Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. N Engl J Med 2001;345:725-730. https://doi.org/10.1056/NEJMoa010187
  15. Park SH, Sohn TS, Lee J, Lim DH, Hong ME, Kim KM, et al. Phase III trial to compare adjuvant chemotherapy with capecitabine and cisplatin versus concurrent chemoradiotherapy in gastric cancer: final report of the adjuvant chemoradiotherapy in stomach tumors trial, including survival and subset analyses. J Clin Oncol 2015;33:3130-3136. https://doi.org/10.1200/JCO.2014.58.3930
  16. Kim KM, Kim MJ, Cho BK, Choi SW, Rhyu MG. Genetic evidence for the multi-step progression of mixed glandular-neuroendocrine gastric carcinomas. Virchows Arch 2002;440:85-93. https://doi.org/10.1007/s004280100540
  17. Furlan D, Cerutti R, Genasetti A, Pelosi G, Uccella S, La Rosa S, et al. Microallelotyping defines the monoclonal or the polyclonal origin of mixed and collision endocrine-exocrine tumors of the gut. Lab Invest 2003;83:963-971. https://doi.org/10.1097/01.LAB.0000079006.91414.BE
  18. Scardoni M, Vittoria E, Volante M, Rusev B, Bersani S, Mafficini A, et al. Mixed adenoneuroendocrine carcinomas of the gastrointestinal tract: targeted next-generation sequencing suggests a monoclonal origin of the two components. Neuroendocrinology 2014;100:310-316. https://doi.org/10.1159/000369071
  19. George J, Walter V, Peifer M, Alexandrov LB, Seidel D, Leenders F, et al. Integrative genomic profiling of large-cell neuroendocrine carcinomas reveals distinct subtypes of high-grade neuroendocrine lung tumors. Nat Commun 2018;9:1048. https://doi.org/10.1038/s41467-018-03099-x
  20. Tang LH, Contractor T, Clausen R, Klimstra DS, Du YC, Allen PJ, et al. Attenuation of the retinoblastoma pathway in pancreatic neuroendocrine tumors due to increased cdk4/cdk6. Clin Cancer Res 2012;18:4612-4620. https://doi.org/10.1158/1078-0432.CCR-11-3264
  21. Finn RS, Aleshin A, Slamon DJ. Targeting the cyclin-dependent kinases (CDK) 4/6 in estrogen receptorpositive breast cancers. Breast Cancer Res 2016;18:17. https://doi.org/10.1186/s13058-015-0661-5
  22. Boscolo-Rizzo P, Da Mosto MC, Rampazzo E, Giunco S, Del Mistro A, Menegaldo A, et al. Telomeres and telomerase in head and neck squamous cell carcinoma: from pathogenesis to clinical implications. Cancer Metastasis Rev 2016;35:457-474. https://doi.org/10.1007/s10555-016-9633-1
  23. Cao Y, Bryan TM, Reddel RR. Increased copy number of the TERT and TERC telomerase subunit genes in cancer cells. Cancer Sci 2008;99:1092-1099. https://doi.org/10.1111/j.1349-7006.2008.00815.x
  24. Verma R, Sharma PC. Next generation sequencing-based emerging trends in molecular biology of gastric cancer. Am J Cancer Res 2018;8:207-225.
  25. Janku F, Hong DS, Fu S, Piha-Paul SA, Naing A, Falchook GS, et al. Assessing PIK3CA and PTEN in earlyphase trials with PI3K/AKT/mTOR inhibitors. Cell Rep 2014;6:377-387. https://doi.org/10.1016/j.celrep.2013.12.035
  26. Blakeley JO, Plotkin SR. Therapeutic advances for the tumors associated with neurofibromatosis type 1, type 2, and schwannomatosis. Neuro Oncol 2016;18:624-638. https://doi.org/10.1093/neuonc/nov200